Pharvaris Q3 2026: €283M Cash, Loss Widens to €47.4M Ahead of April 2027 PDUFA
PHVS sits 52% above its 52-week low of $22.414.
Summary
Pharvaris reported a €47.4M third-quarter loss and €283M in cash as of September 30, 2026, with commercial spending rising ahead of an April 23, 2027 FDA decision on deucrictibant IR.
Key Events · Earnings and Guidance · PHVS
-
Q3 Loss Widens on Commercial Build-Out
Net loss for the quarter was €47.4M (€0.67 per share) versus €37.1M a year earlier, driven by G&A of €17.7M, up 79% year-over-year, and R&D of €32.4M, up 9%.
-
Cash of €283M After €128.8M Burn
Cash and cash equivalents were €283M at September 30, 2026, down from €292M at December 31, 2025, after €128.8M of operating cash use in the nine months.
-
IR PDUFA Date Set for April 23, 2027
The deucrictibant IR NDA for on-demand HAE treatment is under FDA review with a PDUFA action date of April 23, 2027; the EMA MAA is also under formal review.
-
XR Filing and CREAATE Data Timelines Held
The XR NDA for HAE prophylaxis remains on track for 1H2027, and topline data from part 1 of the CREAATE AAE-C1INH study are expected in 1Q2027.
Analysis · PHVS · Life Sciences
The balance sheet still funds the launch build-out and the XR filing without an immediate raise: Pharvaris burned €128.8M of operating cash in the first nine months of 2026 and ended September with €283M. The cost side is the story. G&A jumped 79% year-over-year to €17.7M as the company hires a commercial team for a product that will not generate revenue until the FDA acts on deucrictibant IR, with a PDUFA date of April 23, 2027. Nothing in the pipeline slipped — CHAPTER-3 data remain the basis for an XR NDA in 1H2027 and CREAATE part 1 topline is now guided to 1Q2027 — but the widening loss raises the stakes on that approval, since a delay would force another financing.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHVS was trading at $34.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $22.41 to $43.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.